We took advantage of upregulation of IL-13Rα2 in pancreatic cancer cell lines and hypothesized that HDAC inhibitors may enhance the sensitivity of IL-13 receptor-targeted immunotoxin, IL-13-PE, in pancreatic cancers. This evidence concerns the gene HDAC9 and familial pancreatic carcinoma.